TNFRSF17 and Miyoshi myopathy: Truger’s research, employing whole genome sequencing on penta-refractory MM patients who treated with AMG420 (a BCMA/CD3 BSAB), suggests that a homozygous deletion of the BCMA gene on chromosome 16p underlies the failure of BCMA-targeted T-cell immunotherapy.